Navigation Links
FDA Finds No Link So Far Between Asthma Drugs and Suicide Risk
Date:1/14/2009

Singulair, top-selling drug for teens, plus Accolate and Zyflo show no behavioral changes in trials submitted by manufacturers, agency says; safety review to continue

WEDNESDAY, Jan. 14 (HealthDay News) -- An ongoing U.S. Food and Drug Administration safety review of possible suicidal behavior among those taking asthma drugs has found no evidence of a link so far, agency officials said Tuesday.

The FDA, which began the review in March 2008, said clinical trial data submitted by the manufacturers of Singulair, Accolate and Zyflo suggest the products are not associated with an increased risk of mood changes or suicidal behavior.

But, the agency also noted that the trials were not designed to examine such behavior, and that the safety review will continue, probably for several more months.

"We have finished our analyses of all the data the companies submitted," FDA spokeswoman Karen Riley told the Associated Press. "But that doesn't mean we have closed the book on suicidality."

According to Bloomberg News, Merck & Co submitted results from 41 placebo-controlled trials involving 9,929 patients treated with Singulair, which is the top-selling drug for people under 17 years old. One adult patient treated with Singulair had suicidal thoughts, and there were no suicides, according to the FDA report.

AstraZeneca submitted results from 45 placebo-controlled trials in which 7,540 patients were treated with Accolate. The FDA said one patient in an accompanying placebo group attempted suicide, and another thought about it. No Accolate patients reported any suicidal behavior. The FDA also said Cornerstone submitted information showing no suicidal behavior among Zyflo users.

A Merck executive told the AP Tuesday that the company has turned over extensive records to the FDA.

"We still believe, after a thorough review of our clinical trial data and post-marketing event reports that the safety profile of Singulair hasn't changed," said Dr. Scott Korn, vice president for clinical risk management. "We look forward to discussions with the FDA after they've completed their work."

Before last year's review began, Merck had updated prescribing information for Singulair to include information on several adverse events including tremor, depression, suicidality (suicidal thinking and behavior) and anxiousness, according to the FDA.

When the review began, experts pointed out that while it was under way, asthma sufferers needed to determine with their doctors whether Singulair is the best choice of treatment for them.

"[Patients need] to define what they're taking it for," said Dr. David Weldon, director of the Allergy and Pulmonary Lab Services at Scott & White in College Station, Texas. "In some instances, patients may be prescribed Singulair by itself for management of their asthma, and the expert panel guidelines recommend inhaled steroids as the drug of choice for management of asthma as the first line. So if they're still having problems with asthma, they should check with their prescribing physician regarding this."

Weldon said that he has not seen any increase in psychiatric problems with the drug, but that some patients had complained of nightmares after starting on Singulair.

"The physician really needs to review whether there are symptoms that have developed since patients started taking the medication, if there's an underlying depression that was there before medication started," added Dr. Rauno Joks, chief of the division of allergy and immunology at SUNY (State University of New York) Downstate in New York City. "Also, seasonal allergies in and of themselves can cause fatigue and lethargy, which makes it harder to assess, because those are some of the symptoms you have with depression."

Joks said he had seen headaches develop as a side effect of Singulair, but not psychiatric problems.

The drug, a leukotriene receptor antagonist that targets part of the body's inflammatory process, is prescribed to treat asthma and the symptoms of allergic rhinitis, as well as to prevent exercise-induced asthma.

More information

Visit the FDA for more on this issue.



SOURCES: Bloomberg News; Associated Press; David Weldon, M.D., assistant professor, internal medicine, Texas A&M Health Science Center College of Medicine and director, Allergy and Pulmonary Lab Services, Scott & White, College Station; Rauno Joks, M.D., associate professor of clinical medicine, and chief, division of allergy and immunology, SUNY (State University of New York) Downstate, New York City


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. MRI finds breast cancer before it becomes dangerous
3. RAND finds cases of undiagnosed diabetes drop sharply
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Ability to cope with stress can increase good cholesterol in older white men, study finds
6. Pitt study finds inequality in tobacco advertising
7. Study finds some kids are being misdiagnosed with asthma
8. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
9. Parents perceptions can hamper kids asthma care, study finds
10. Study finds primary care depression treatment often does not follow quality guidelines
11. Study of Studies Finds No Risk to Children From Phthalates in Toys
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Finds No Link So Far Between Asthma Drugs and Suicide Risk
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... with biotechs, drug manufacturers, health insurance companies all falling ... very small healthcare companies. While not often talked about, ... The United States is by ... the world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
Breaking Medicine Technology: